Marathon Patent Group Inc. (NASDAQ:MARA)’s Q3 Revenues Grows 280%

Marathon Patent Group Inc. (NASDAQ:MARA)

Marathon Patent Group Inc. (NASDAQ:MARA) traded higher after the company reported Q3 financial results that beat Wall Street expectations. Shares of the company gained 5.04% in Monday’s trading session to end the day at $1.46 a share.

Marathon Patent Group Inc. (NASDAQ:MARA)

MARA Stock Performance

The company generated revenues of $163 million for the three months ended September 30, 2017, up from revenues of $43,000 reported in Q3 2016. Operating loss for the period dropped to $3.9 million, compared to $10.7 million reported last year.

Despite the 5% rally, Marathon Patent Group Inc. (NASDAQ:MARA) is still trading in a downtrend. The IP licensing company has shed more than 70% in market value and is currently trading near its 52-week low of $0.50 a share.

Last month, the company was forced to initiate a reverse stock-split of its common stock in a bid to shore up its share price. The split was primarily intended to bring the company in compliance with the minimum average closing share price for continued listing in the NASDAQ Capital Market. A 4:1 reverse stock-split consequently reduced the company’s common stock from approximately 32.4 million shares to approximately 8.6 million shares.

Investor’s sentiments on the stock appear to have hit all-time lows despite the company making huge strides on revenue growth. It awaits to be seen if the stellar Q3 financial results is the catalyst that will help push the stock from current lows.

GBV Acquisition

In a bid to strengthen investor confidence in the stock, Marathon Patent Group Inc. (NASDAQ:MARA) announced the acquisition of Global Bit Ventures. The acquisition is part of the company’s plan to diversify its areas of operations. The company is currently eyeing growth opportunities in the digital currency space with the acquisition.

Global Bit Ventures joins Marathon Patent Group Inc. (NASDAQ:MARA) with a robust infrastructure around cryptocurrencies, with significant capability for expansion. The company boasts of a technology that powers and secures blockchains by operating custom hardware and software. It also owns 250GH/s of GPU mining servers.

“We previously expressed our intent to review alternative business directions with the goal of enhancing shareholder value. We believe the acquisition of Global Bit Ventures will take advantage of an ongoing revolution in digital transactions conducted on blockchains as we see increasing adoption and proliferation of blockchain protocols in our everyday lives,” said CEO, Doug Croxall.

According to GBV CEO, the merger marks an important milestone and sets the company on course for accelerated revenue growth

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $MARA and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Jaguar Health Inc. (NASDAQ:JAGX)

Jaguar Health Inc. (NASDAQ:JAGX) Reports Stellar Q3 Financial Results

Jaguar Health Inc. (NASDAQ:JAGX)

Jaguar Health Inc. (NASDAQ:JAGX) fell 2.7% after reporting its first quarterly financial results after merging with Napo Pharmaceuticals. The commercial stage natural-products pharmaceuticals company generated a net income of $4.75 million for the three months ended September 30, 2017.

Jaguar Health Inc. (NASDAQ:JAGX)

Jaguar’s Revenue Growth

Jaguar Health Inc. (NASDAQ:JAGX) is still trading in a downtrend despite posting stellar financial results for the third quarter. The stock has shed more than 50% in market value since the start of the year as short sellers continue to push the stock lower. It awaits to be seen, the kind of impact that the Napo Pharmaceuticals merger will have on investor sentiments in the stock heading into the year-end.

According to data compiled by Zacks Investment Research, despite the underperformance, Jaguar Health Inc. (NASDAQ:JAGX) is currently rated as a “Strong Buy” by two analysts.

Net revenue in the quarter came in at $1.1 million made up of $346,000 for Mytesi, $82,000 for Neonorm and approximately $655,000 in collaboration revenue. Total net revenue for the third quarter of 2016 was $50,000. Average sales of Mytesi have increased over 50% since August.

“With the onboarding of three additional HIV sales personnel this month, and the refilling rate of Mytesi® prescriptions for a chronic disease, we expect continued growth for future Mytesi® sales,” said Lisa Conte, Jaguar Health Inc. (NASDAQ:JAGX)’s president, and CEO.

Mytesi revenue continues to increase because of increased marketing, advertising, medical education and promotional activities. Mytesi is a prescription treatment for diarrhea that works by normalizing the flow of water in the GI tract. It is the only FDA approved antidiarrheal therapy for the symptomatic relief of non-infectious diarrhea in adult patients.

For the first nine months of the year, revenue increased to $2.8 million compared to $113,000 reported last year. Jaguar Health Inc. (NASDAQ:JAGX) expects further growth in revenue heading into the year-end due to an increase in human-product revenue.

HIV Scientific Advisory Board

Separately, Dr. Roscoe Moore has joined the HIV Scientific Advisory board recently formed by Jaguar Health Inc. (NASDAQ:JAGX)’s wholly owned subsidiary, Napo Pharmaceuticals. The board will focus on physician education and global awareness regarding the importance and availability of solutions for neglected comorbidities.

“Neglected comorbidities such as HIV-related diarrhea play a significant role in patient adherence to ART Efforts to expand awareness about available solutions, such as Mytesi®, that address specific comorbidities play an important role in maximizing health and wellness in this population,” said Dr. Moore.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $JAGX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Eleven Biotherapeutics Inc (NASDAQ:EBIO)

Eleven Biotherapeutics Inc (NASDAQ:EBIO) Reports Q3 Earnings

Eleven Biotherapeutics Inc (NASDAQ:EBIO)

Eleven Biotherapeutics Inc (NASDAQ:EBIO) shares dropped over 7%, on heavy volume, after the biotech company reported their Q3 2017 financial results. EBIO shares opened at $0.74, then dropped to a low of $0.64 before closing at $0.69. At current levels, EBIO shares are trading below their published cash per share value of $0.71, and their book value per share figure of $1.05.

Eleven Biotherapeutics Inc (NASDAQ:EBIO)

Eleven Biotherapeutics Inc (NASDAQ:EBIO) is a late-stage, clinical oncology company that develops therapies for cancer patients based upon the company’s proprietary targeted protein therapeutics (TPTs) platform. The company’s TPTs incorporate a tumor-targeting antibody fragment and a cytotoxic protein payload within a single protein molecule in order to achieve focused tumor cell killing. Eleven Biotherapeutics believes its TPT approach offers significant advantages in treating cancer over existing antibody drug conjugate technologies. Eleven Biotherapeutics promotes the idea that its TPTs provide effective tumor targeting with broader cancer cell-killing properties than generally achievable other treatments that require tumor cell proliferation to be effective and can face challenges overcoming multi-drug resistance mechanisms within tumor cells.

In November, Eleven Biotherapeutics Inc (NASDAQ:EBIO) completed a public offering of 5,525,000 shares of its common stock, pre-funded warrants to purchase an aggregate of 4,475,000 shares of common stock, and common warrants to purchase up to an aggregate of 10,000,000 shares of common stock, raising approximately $8.0 million in gross proceeds and $7.0 million in net proceeds.

Eleven Biotherapeutics Q3 Earnings

Eleven Biotherapeutics Inc (NASDAQ:EBIO) did not record any revenue for Q3 2017. In Q3 2016, the company reported revenue of $28.7 million. This difference was due to revenue recognized in 2016 from the company’s license agreement with Roche. Roche’s next licensing milestone payment will be triggered upon commencement of a Phase 2 clinical trial by Roche.

Net loss for Q3 2017 was (-$9.1) million, or (-$0.37) per share, versus net income of $19.5 million, or $0.95 per basic share and $0.91 per diluted share, for the same period in 2016. The change was primarily the result of revenue recognized in 2016 from the company’s license agreement with Roche.

Research and development expenses were $3.6 million, compared to $2.8 million for the same period in 2016. Cash and cash equivalents were $11.3 million.

EBIO Stock Performance

Per share earnings for the biotech company have been on an upward trend ever since 2013, when the company reported a loss of (-$16.19). Losses contracted annually and in 2016 a EPS profit of $0.01 was posted. Last year, due to the Roche licensing agreement, the company reported some sales of $30 million. A number that that could be considered “material” for the first time in its existence. However, the company has a consistent history of diluting shareholder equity. In 2013 the number of outstanding shares stood at 1.35 million, then continued to expand on an annual basis. In 2016 the company ended the year with 21.08 million shares outstanding.

For the year, EBIO shares have lost 70%, and, for the month, the shares have lost 45% in value. Despite performance that lags the markets, and its sector, EBIO shares are rated “Market Perform” and “Strong Buy” by the two investment firms that follow the company. Their consensus, one-year price target is $12.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $EBIO and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

China Advanced Constructn Mtrls Grp Inc. (NASDAQ:CADC) Market Value Almost Triples!

China Advanced Constructn Mtrls Grp Inc. (NASDAQ:CADC) Market Value Almost Triples!

China Advanced Constructn Mtrls Grp Inc. (NASDAQ:CADC)

China Advanced Constructn Mtrls Grp Inc. (NASDAQ:CADC) shares nearly tripled in market value after the holding company reported Q3 financial results that exceeded Wall Street expectations. Revenue for the three months ended September 30, 2017, nearly doubled as net loss dropped by two thirds.

China Advanced Constructn Mtrls Grp Inc. (NASDAQ:CADC) Market Value Almost Triples!

CADC Stock Performance

China Advanced Constructn Mtrls Grp Inc. (NASDAQ:CADC) stock is currently trading at this year’s highs and close to its 52-week high of high of $9.75 a share. The better than expected financial results appear to have strengthened investor confidence in the company, as the stock had been trading in a downtrend.

Over the past one month, the stock has performed along a premium change of 7.5%. For the past three months, the stock is up by more than 13.1%. However, it is down by 6.5% for the past six months.

The stock grabbed analysts’ attention after spiking on unusual volume. More than 19.31 million shares exchanged hands in Thursday’s trading session compared to a 3-month average volume of 0.02 million and a daily average trading volume of 15.5k shares.

China Advanced Constructn Mtrls Grp Inc. (NASDAQ:CADC) conducts its primary business through subsidiaries. The company engages in the production of construction materials for infrastructure, commercial and residential developments.

Government and industry associations have certified the company’s products. It also boasts of a leading position in the large, highly fragmented ready-mix market concrete market.

CADC Q3 Financial Results

For the three months ended September 30, 2017, the construction company reported revenues of $13.8 million, up from revenues of $7.5 million reported in the corresponding period last year. Cost of revenue surged to $12.3 million from $8.41 million. China Advanced Constructn Mtrls Grp Inc. (NASDAQ:CADC) generated a gross profit of $1.4 million compared to $952,412 reported last year.

“Our management believes that we have the ability to capture a greater share of the Beijing market via expanding relationships and networking, signing new contracts, and continually developing market-leading innovative and eco-friendly ready-mix concrete products,” China Advanced Constructn Mtrls Grp Inc. (NASDAQ:CADC) in a statement.

Net loss for the three months ended September came in at $545,590 compared to a net loss of $5.3 million reported last year. China Advanced Construction Materials exited the quarter with cash and cash equivalent of $923,882 compared to $8.2 million as of the same period last year.

China Advanced Constructn Mtrls Grp Inc. (NASDAQ:CADC) has a Return on Assets of -25.40%. Return on Investment currently stands at -20.55 which means its operations costs outweigh returns.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CADC and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Arca Biopharma Inc. (NASDAQ:ABIO)

Arca Biopharma Inc. (NASDAQ:ABIO) Awarded European Patent

Arca Biopharma Inc. (NASDAQ:ABIO)

Arca Biopharma Inc. (NASDAQ:ABIO) traded higher after the European Patent Office granted it a patent on methods for treating cardiovascular disease with a thiol-substituted isosorbide mononitrate. Shares of the company gained 20.83% to end Thursday’s trading session at $1.45 a share.

Arca Biopharma Inc. (NASDAQ:ABIO)

ABIO Stock Performance

Thursday’s rally capped yet another impressive run as the stock continues to bounce back from yearly lows. Arca Biopharma Inc. (NASDAQ:ABIO) has shed more than 40% in market value since the start of the year as short sellers continue to apply pressure. The stock is currently trading in a downtrend and faces immediate resistance at $1.60.

The new European Patent appears to have revitalized investors’ confidence in the stock. Titled Methods of and Compositions for Cardiovascular Disease and Conditions, the patent provides protection for Arca Biopharma Inc. (NASDAQ:ABIO) approach for treating patients with cardiovascular diseases and conditions.

AB171 Development

The biopharmaceutical company has discovered what it believes is a pharmacogenetic target for AB171, which can be used in genetically targeted cardiovascular development programs. ARCA plans to advance the development of AB171 for the treatment of peripheral arterial disease and for chronic heart failure.

“The addition of AB171 to our genetically-targeted development pipeline, including the Gencaro atrial fibrillation-heart failure program, is consistent with that mission. We believe our experience with GENETIC-AF has established the feasibility of in-house design and execution of pharmacogenetic clinical trials, and has provided invaluable insights into this type of drug development,” said CEO, Michael Bristow.

Arca Biopharma Inc. (NASDAQ:ABIO) expects top-line results on a Phase 2B Genetic-AF trial in the latter part of the first quarter of 2018. The Phase 2B trial will be investigating the safety and efficacy of Gencaro to Toprol-XL for the treatment and prevention of atrial fibrillation or heart flutter.

“We are focused on executing our genetically-targeted approach to cardiovascular drug development and look forward to furthering our development of Gencaro as well as initiating additional pharmacogenetic development programs..,” said Mr. Brostow.

Arca Q3 Financial Results

Separately, Arca Biopharma Inc. (NASDAQ:ABIO) reported a net loss of (-$4.4) million or (-$0.39) a share, for the three months ended September 30, 2017. Net loss for the first nine months of the year came in at (-$14.3) million compared to a net loss of (-$12.2) million for the corresponding period last year. Research and development expenses for the quarter totaled $3.5 million compared to $3.7 million for Q3 2016.

Arca Biopharma Inc. (NASDAQ:ABIO) exited the quarter with cash and cash equivalent of $16 million compared to $23.5 million as of December 31, 2016. The cash balance is sufficient to fund operations and projected cost structure through the end of the second quarter of 2018.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ABIO and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Egalet Corp (NASDAQ:EGLT)

Egalet Corp (NASDAQ:EGLT) Moves on Topline Trial Results

Egalet Corp (NASDAQ:EGLT)

Egalet Corp (NASDAQ:EGLT) was a big mover after announcing top-line trial results from a phase 3 safety study of its abuse-deterrent oxycodone formulation Egalet-002. Shares of the company gained 38.55% after it emerged the formulation was well tolerated, and adverse events reported were consistent with expected outcomes.

Egalet Corp (NASDAQ:EGLT)

Egalet-002 Top Line Results

According to the Chief Executive Officer, Bob Radie, the positive Phase 3 safety study results validates the company’s Guardian technology, which is being used to develop abuse-deterrent formulations of prescription medications.

Last year, Egalet Corp (NASDAQ:EGLT) reported positive top-line result from a category 3 intranasal human abuse potential study of Egalet. The formulation is currently in late-stage development for the management of pain severe enough to require daily, long-term opioid treatment for which other treatment options are inadequate.

Despite the 38% rally, Egalet Corp (NASDAQ:EGLT) continues to trade in a downtrend after underperforming the overall industry for the better part of the year. The stock has shed more than 80% in market value since the start of the year and is currently trading near all-time lows. Shares of the company closed at $1.15, last year they were trading at $5.58 a share.

Despite the underperformance, the Chief Executive Officer remains bullish about the company’s long-term prospects as they move to address the prescription abuse crisis.

“With 124% prescription growth and 41% revenue growth for our marketed products over last year’s third quarter, we continue to grow our business With a cash position of $102.1 million and the increased focus on non-narcotic and innovative treatments to alleviate pain,” said Mr. Radie

For the three months ended September 30, 2017, Egalet Corp (NASDAQ:EGLT) registered a 101% increase in Nasal Spray prescriptions over the third quarter of 2016. The company also partnered Ascend Therapeutics to begin promotion of SPRIX Nasal Spray to over 11,000 target women healthcare providers.

Egalet Q3 Financial Results

Net product sales for the third quarter came in at $6.7 million compared to $4.7 million reported last year. Cost of sales was $1.2 million up from $914,000 as of last year and reflected the average cost of inventory produced and dispensed to patients. General and Administrative expenses dropped to $6.8 million from $8 million as of the corresponding period last.

Egalet Corp (NASDAQ:EGLT) generated a net loss of (-$18.9) million in Q3 2017 or (-$0.46) a share, compared to a net loss of (-$26.9) million or (-$1.10) reported last year. The earnings exceeded Wall Street expectations as analysts were expecting a net loss of (-$0.47) cents a share. The integrated specialty pharmaceutical company exited the quarter with cash and cash equivalent of $102.1 million.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $EGLT and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Avid Technology, Inc. (NASDAQ:AVID)

Avid Technology, Inc. (NASDAQ:AVID) Unveils New Video-over-IP Interface

Avid Technology, Inc. (NASDAQ:AVID)

Shares of Avid Technology, Inc. (NASDAQ:AVID) gained 14.74% after the global media technology provider unveiled its latest addition to the Avid I/O family of hardware interfaces. Avid Artist DNxIP is the new Thunderbolt 3 equipped I/O device, designed to enable the transfer of SMPTE standard HD video over 10GigE IP networks.

Avid Technology, Inc. (NASDAQ:AVID)

Avid Artist DNxIP

Built in partnership with AJA and powered by MediaCentral, Avid Artist DNxIP should eliminate the challenges of managing physical resources commonly associated with legacy video routing. It should also give customers more flexibility in the way they route video within their facilities.

“DNxIP is the next evolution of our development efforts with Avid, a trusted technology partner. We’re excited to be teaming up with them again on a next-generation hardware option that meets the needs of professional IP workflows,” said Nick Rashby, President, and AJA Video Systems.

Avid Technology, Inc. (NASDAQ:AVID) has received a lot of attention due to the recent volatility of its stock. AVID stock is currently trading in an uptrend after gaining more than 40% in market value since the start of the month. For the full year, the stock is up by more than 30%.

Stellar Q3 Results

Renewed investor interest in the stock follows the announcement of better than expected third quarter financial results. Avid Technology, Inc. (NASDAQ:AVID) exceeded guidance on revenue and bookings in the recent quarter as it recorded growth in key metrics. Improvement in adjusted EBITDA drove the company to the fourth consecutive quarter of positive adjusted cash flow.

Avid Technology reported a net income of $72,000 for the third quarter as revenue came in at $105.3 million, above the upper-end of guidance. During the quarter, the company signed several multiyear deals that are expected to lead to further revenue growth in the fourth quarter.

For the fourth quarter, Avid Technology, Inc. (NASDAQ:AVID) expects bookings of between $112 million and $126 million and revenues of between $103 million and $113 million.

“The completion of the transformation in the second quarter of 2017 has positioned us to drive profitable growth, increase revenue visibility and cash flow. In the third quarter, we achieved meaningful growth across bookings, revenue excluding pre-2011 and eliminating PCS, adjusted EBITDA and adjusted free cash flow,” said CEO, Louis Hernandez.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $AVID and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Sorl Auto Parts, Inc. (NASDAQ:SORL) Raises Guidance after Stellar Q3

Sorl Auto Parts, Inc. (NASDAQ:SORL)

Shares of Sorl Auto Parts, Inc. (NASDAQ:SORL) gained 20.4% after the leading manufacturer and distributor of automotive brake systems reported Q3 financial results that beat Wall Street estimates. According to the Chief Executive Officer, Xiaoping Zhang, demand for the company’s products continue to increase across all three business segments.

Sorl Auto Parts, Inc. (NASDAQ:SORL)

Sorl Sales Growth

Investors reacted to the better than expected financial results by pushing the stock up the chart, after coming under pressure in recent weeks. The stock is currently trading in an uptrend with immediate resistance at $8.40, above which it could make a push for the 52-week high of $9.74 a share. For the full year, the stock is up by more than 90%.

For the three months ended September 30, 2017, Sorl Auto Parts, Inc. (NASDAQ:SORL) generated sales of $101.3 million – representing a 59% year over year growth. Revenues from international markets increased 19.1% to $19.3 million due to growing global customer base. Net sales for the first nine months of the year increased 29.6% to $72.9 million.

Gross profit in the quarter grew 44.4% to $27.3 million compared to $18.9 million reported last year. However, gross margin dropped to 26.9% from 29.7% due to higher raw materials costs and price promotion designed to increase market share.

“We are excited to report that our sales growth in all three segments accelerated during the quarter. We continue to capture market share in the Chinese commercial vehicle braking market with our new advanced products and attractive pricing,” said Mr. Zhang.

New Guidance

Net income attributed to shareholders increased 165% to $8.6 million or $0.44 a share compared to $3.2 million or $0.17 a share reported last year. Net income for the first nine months of the year nearly doubled to $21.4 million or $1.11 a share from $10.9 million or $0.57 a share reported last year.

Sorl Auto Parts, Inc. (NASDAQ:SORL) exited the third quarter with cash and cash equivalent of $7.6 million. Inventories in the quarter increased to $83.1 million from $65.8 million as of December 31, 2018.

Buoyed by the strong performance in the third quarter, Sorl Auto Parts, Inc. (NASDAQ:SORL) management has increased its full-year guidance for net sales, from $315 million to approximately $370 million. The company also expects net income of $30.5 million up from an initial guidance of $27.5 million.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $SORL and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Quest Resource Holding Corp (NASDAQ:QRHC)

Quest Resource Holding Corp (NASDAQ:QRHC) Makes Large Gains

Quest Resource Holding Corp (NASDAQ:QRHC)

Quest Resource Holding Corp (NASDAQ:QRHC) stock has gained over 70% after the waste management company released their Q3 2017 earnings report. QRHC shares gapped up to open at $1.48, then continued to rise to $2.91 before sellers stepped in. QRHC stock has been trading in a range between $1.90 and $2.10 since 10:30 AM EST. Volume is enormous. The stock normally trades about 38,000 shares per day, but with two hours left in today’s trading session, over 6.1 million shares have exchanged hands.

Quest Resource Holding Corp (NASDAQ:QRHC)

Quest Resource Q3 Financial Report

EPS for Q3 2017 was forecast by analysts at (-$0.07) and that is exactly what the company reported. Net loss improved by $1.3 million to (-$1.1) million compared with a net loss of (-$2.4) million for the third quarter of 2016. During the third quarter of 2017, operating expenses were $5.0 million, a decrease of $1.0 million, or 16%, compared with the third quarter of 2016. Adjusted EBITDA improved by $786,000 to $513,000 compared with a loss of (-$273,000) for Q3 2016.

Quest Resource Holding Corp (NASDAQ:QRHC) provides recycling and disposal services for a range of waste streams and recyclables generated by businesses. The company also operates social media and online digital platforms that contain information and instructions to recycle or properly dispose of household products and materials. Its services focuses on the waste streams and recyclables from big box, food chain, and other retailers.

QRHC Stock Performance

Year-to-date, QRHC stock is down over 50%. However, two investment forms cover Quest Resource Holding Corp (NASDAQ:QRHC) and both rate the shares as a “Strong Buy” with a consensus, one-year price target of $6.00. The stock’s 52-week low is $1.03, and its 52-week high is $3.00.

Quest Resource Holding Corp (NASDAQ:QRHC) has a market capitalization of less than $20 million but annual sales of over $175 million. Unfortunately, earnings have been challenging. In 2012 is lost (-$5.92) per share, and last year the loss was a more modest (-$0.55).

Stock dilution has been an issue for shareholders. In 2012, 7.12 million shares were outstanding. By the end of 2016, that number was 14.74 million.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $QRHC and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

SemiLEDs Corporation (NASDAQ:LEDS)

Shares of SemiLEDs Corporation (NASDAQ:LEDS) Booming!

SemiLEDs Corporation (NASDAQ:LEDS)

SemiLEDs Corporation (NASDAQ:LEDS) stock is up over 1700% after the memory chip manufacturer announced it would be releasing their Q4, 2017 financial results after the market close. LEDS stock was trading below yesterday’s close until the company made the announcement, then the stock shot up from $2.75 to over $7.50 just after 12:30PM EST. Volume is over 130 times the daily listed average.

SemiLEDs Corporation (NASDAQ:LEDS)

SmeiLEDS Files Preliminary Results

However, prior to this morning’s announcement, SemiLEDs Corporation (NASDAQ:LEDS) filed an 8-K form with the SEC and provided preliminary results for the quarter ended August 31, 2017. Revenue for Q4 2017 was $2.6 million, a 22% increase compared to $2.1 million for Q3 2017. GAAP net loss attributable to SemiLEDs stockholders for the fourth quarter of fiscal 2017 was (-$0.7) million, compared to a loss of (-$1.6) million for Q3 2017, or a net loss of (-$0.19) per diluted share, compared to a net loss of (-$0.45) per diluted share for Q3 2017. Cash and cash equivalents was $3.6 million as of August 31, 2017, compared to $3.1 million at the end of the third quarter of fiscal 2017. The net cash inflows in operating activities were $0.5 million in the fourth quarter of fiscal 2017, compared with net cash outflows $0.9 million in the third quarter of fiscal 2017.

SemiLEDs Corporation (NASDAQ:LEDS), based in Chunan, Taiwan, develops and manufactures LED chips and LED components primarily for general lighting applications, including street lights and commercial, industrial and residential lighting, along with specialty industrial applications such as ultraviolet (UV) curing, medical/cosmetic, counterfeit detection, horticulture, architectural lighting and entertainment lighting. SemiLEDs sells blue, white, green and UV LED chips.

LEDS Stock Performance

Sales have been declining for SemiLEDs Corporation (NASDAQ:LEDS). In 2012, the company reported sales of $29.3 million. For 2016, the company’s sales were only $10.1 million. However, with one exception, EPS losses have been contracting annually. In 2012 the EPS loss was (-$18.04), and that number shrank to (-$7.25) by 2016.

Over the past quarter, LEDS stock has performed well – gaining over 30%. Unfortunately, the shares are down over 20% for the year.

It should also be noted that, as of the market open, LEDS stock had a sizeable short seller position of over 20% of the stock’s float.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $LEDS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.